European Commission Grants Marketing Authorization for Adcomfo (Omalizumab)
The European Commission has approved Adcomfo, a biosimilar to XOLAIR developed by Kashiv BioSciences in collaboration with Alvotech, for the treatment of several conditions.
Stocks · News reference
Alvotech reported financial results for the first nine months of 2026, noting adjusted total revenue of $323.4 million and maintaining its full-year 2026 guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The European Commission has approved Adcomfo, a biosimilar to XOLAIR developed by Kashiv BioSciences in collaboration with Alvotech, for the treatment of several conditions.
Investment firm Jefferies has initiated coverage on Alvotech, assigning the stock a 'Buy' rating and a price target of $9.
Alvotech management will participate in the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference in November 2026.
Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its management team will participate in four major investor conferences across Europe in November 2026, including presentations at UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, DNB Carnegie Healthcare Conference, and SEB Healthcare Seminar. Live audio webcasts will be available on the company's website.
Alvotech, a global biotechnology company specializing in biosimilar medicines, will present at four international investor conferences in November 2026 across the UK, Norway, and Sweden. The company will participate in UBS's biotech conference in London, Jefferies' healthcare conference in London, DNB Carnegie's healthcare conference in Oslo, and SEB's healthcare conference in Stockholm. Live streams and recordings of these presentations will be available on the company's events page.